FDA approves PLC's smaller TMR (transmyocardial revascularisation) laser:
This article was originally published in Clinica
The US FDA has approved for sale PLC Medical Systems' next-generation CO2 laser for transmyocardial revascularisation. The new product is less than half the weight of the company's first-generation laser and can be moved easily between surgical suites, allowing cardiac surgeons to decide intra-operatively whether to use the device to treat areas of the myocardium not addressed by bypass surgery. The Franklin, Massachusetts-based company's device will be distributed throughout the US by Edwards LifeSciences.